{
    "root": "a78acad9-1758-41b3-943b-f47bffa86909",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tizanidine",
    "value": "20231109",
    "ingredients": [
        {
            "name": "TIZANIDINE HYDROCHLORIDE",
            "code": "B53E3NMY5C",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9609"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        }
    ],
    "indications": {
        "text": "tizanidine tablets , usp central alpha-2-adrenergic agonist indicated management spasticity . short duration therapeutic effect , treatment tizanidine tablets , usp reserved daily activities times relief spasticity important [ ( 2.1 ) ] .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 recommended starting dose : 2 mg ; dose repeated 6 8 hour intervals , maximum 3 doses 24 hours ( 2.1 ) \u2022 increased 2 mg 4 mg per dose , 1 4 days increases ; total daily dose exceed 36 mg ( 2.1 ) \u2022 tizanidine pharmacokinetics differs tablets capsules , taken without food . differences could result change tolerability control symptoms ( 2.1 , 12.3 ) \u2022 discontinue tizanidine tablets , usp , decrease dose slowly minimize risk withdrawal rebound hypertension , tachycardia , hypertonia ( 2.2 )",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "tizanidine tablets , usp 4 mg available ; white off-white , round , flat beveled , uncoated tablets debossed product code \u201c 503 \u201d one side , quadrisecting score . ndc : 71335-1016-1 : 30 tablets bottle ndc : 71335-1016-2 : 60 tablets bottle ndc : 71335-1016-3 : 90 tablets bottle ndc : 71335-1016-4 : 120 tablets bottle ndc : 71335-1016-5 : 20 tablets bottle ndc : 71335-1016-6 : 45 tablets bottle ndc : 71335-1016-7 : 140 tablets bottle ndc : 71335-1016-8 : 84 tablets bottle ndc : 71335-1016-9 : 28 tablets bottle ndc : 71335-1016-0 : 112 tablets bottle repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "tizanidine tablets , usp contraindicated patientstaking potent inhibitors cyp1a2 , fluvoxamine ciprofloxacin [ ( 7.1 , 7.2 ) ] .",
    "indications_original": "Tizanidine Tablets, USP is a central alpha-2-adrenergic agonist indicated for the management of spasticity. Because of the short duration of therapeutic effect, treatment with Tizanidine Tablets, USP should be reserved for those daily activities and times when relief of spasticity is most important [see Dosage and Administration(2.1)].",
    "contraindications_original": "\u2022 Recommended starting dose: 2 mg; dose can be repeated at 6 to 8 hour intervals, up to a maximum of 3 doses in 24 hours (2.1) \u2022 Dosage can be increased by 2 mg to 4 mg per dose, with 1 to 4 days between increases; total daily dose should not exceed 36 mg (2.1) \u2022 Tizanidine pharmacokinetics differs between tablets and capsules, and when taken with or without food. These differences could result in a change in tolerability and control of symptoms ( 2.1 , 12.3 ) \u2022 To discontinue Tizanidine Tablets, USP, decrease dose slowly to minimize the risk of withdrawal and rebound hypertension, tachycardia, and hypertonia ( 2.2 )",
    "warningsAndPrecautions_original": "Tizanidine Tablets, USP 4 mg are available as; white to off-white, round, flat beveled, uncoated tablets debossed with product code \u201c503\u201d on one side, and quadrisecting score on the other.\n                  NDC: 71335-1016-1: 30 Tablets in a BOTTLE\n                  NDC: 71335-1016-2: 60 Tablets in a BOTTLE\n                  NDC: 71335-1016-3: 90 Tablets in a BOTTLE\n                  NDC: 71335-1016-4: 120 Tablets in a BOTTLE\n                  NDC: 71335-1016-5: 20 Tablets in a BOTTLE\n                  NDC: 71335-1016-6: 45 Tablets in a BOTTLE\n                  NDC: 71335-1016-7: 140 Tablets in a BOTTLE\n                  NDC: 71335-1016-8: 84 Tablets in a BOTTLE\n                  NDC: 71335-1016-9: 28 Tablets in a BOTTLE\n                  NDC: 71335-1016-0: 112 Tablets in a BOTTLE\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Tizanidine Tablets, USP is contraindicated in patientstaking potent inhibitors of CYP1A2, such as fluvoxamine or ciprofloxacin [\n                        see  Drug Interactions (7.1 ,  7.2 )\n                     ].",
    "drug": [
        {
            "name": "Tizanidine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63629"
        }
    ]
}